Potential Value of miR-221/222 as Diagnostic, Prognostic, and Therapeutic Biomarkers for Diseases

microRNAs (miRNAs) are short non-coding RNAs that regulate gene expression by base pairing with their target messenger RNAs. Dysregulation of miRNAs is involved in the pathological initiation and progression of many human diseases. miR-221 and miR-222 (miR-221/222) are two highly homologous miRNAs,...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 8; p. 56
Main Authors Song, Jialin, Ouyang, Yuanming, Che, Junyi, Li, Xiaoming, Zhao, Yi, Yang, Kejia, Zhao, Xiaotian, Chen, Yinghui, Fan, Cunyi, Yuan, Weien
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 16.02.2017
Subjects
Immunology
microRNAs
therapy
diagnosis
diseases
biomarker
prognosis
miR-221/222
Online AccessGet full text

Cover

More Information
Summary:microRNAs (miRNAs) are short non-coding RNAs that regulate gene expression by base pairing with their target messenger RNAs. Dysregulation of miRNAs is involved in the pathological initiation and progression of many human diseases. miR-221 and miR-222 (miR-221/222) are two highly homologous miRNAs, and they are significantly overexpressed in several types of human diseases. Silencing miR-221/222 could represent a promising approach for therapeutic studies. In the present review, we will describe the potential value of miR-221/222 as diagnostic, prognostic, and therapeutic biomarkers in various diseases including cancer and inflammatory diseases.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Francesca Lovat, Ohio State University, USA; Satoshi Fukushima, Kumamoto University, Japan
Specialty section: This article was submitted to Inflammation, a section of the journal Frontiers in Immunology
These authors have contributed equally to this work.
Edited by: Kai Fang, University of California Los Angeles, USA
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2017.00056